

# Trivedon-20

Trimetazidine 20 mg tablets

The vital addition that protects the heart

## Role of Trimetazidine in PTCA and CABG

Reperfusion during revascularisation procedures often results in reperfusion damage<sup>1</sup>

### Nature of Reperfusion Injury<sup>1,2</sup>

- Arrhythmia
- Acceleration of necrosis in tissue that has already sustained lethal injury
- Unfavorable but reversible contractile and metabolic events
- Cell death in potentially viable tissue

### Causes of Reperfusion Injury<sup>3,4</sup>

- Increased production of free radicals
- Inflammation - release of polymorphonuclear leucocytes
- Calcium overload



### Actions of Trimetazidine<sup>5</sup>

- Limits overproduction of free radicals
- Prevents infiltration of polymorphonuclear leucocytes
- Reduces calcium overload

### Clinical benefits of Trimetazidine

#### Trimetazidine improves the outcome of PTCA<sup>6</sup>

- Delays the onset and magnitude of ischemic response



The change in the magnitude of ST segment shift, measured via the ic. ECG, in the placebo and trimetazidine-treated groups during balloon inflations  $D_1$  (Orange line, before drug administration) and  $D_2$  (Green line, after placebo or trimetazidine treatment).


# Trivedon-20

Trimetazidine 20 mg tablets

The vital addition that protects the heart


## Trimetazidine in CABG<sup>7</sup>

### Limits cellular damage



Presence of myosin in the venous blood 4 hours after surgery

### Reduces free radical-induced reperfusion injury



Malondialdehyde (MDA) levels measured in coronary sinus blood before surgery and 20 min after reflow (mean + SEM)

## Conclusion

### Trimetazidine is of potential use in revascularisation procedures

- Limits ischemia during Percutaneous Transluminal Coronary Angioplasty
- Reduces reperfusion damage during Coronary Artery Bypass Grafting

## Cipla – Your Healthcare Partner Since 1935

Produced by CIPLA, a leading provider of generic pharmaceuticals.

### Key Facts about CIPLA:

- 25 manufacturing facilities approved by leading regulatory authorities including the FDA (USA), MHRA (U.K.) and TGA (Australia).
- Over 1000 Formulations and 150 actives Active Pharmaceutical Ingredients.
- Prequalified and Approved by the World Health Organisation (WHO) for supply to UN Agencies.
- The World's largest range of antiasthmatic aerosols and inhalation devices.
- The World's largest manufacturer of antiretroviral drugs and supplier to the Clinton Foundation AIDS/HIV Initiative.

#### Distributed by

Controlled Medications Ltd  
Unit 204, 2/F New Bright Building  
11 Sheung Yuet Road, Kowloon Bay  
Kowloon, Hong Kong  
Tel: (852) 2896 0889  
Fax: (852) 2898 9842  
www.swedishtrading.com/conmed

**conmed**  
Controlled Medications Ltd.  
康德行有限公司

#### Bibliography:

1. Am J Cardiology 1998; 82(5A) : 1K
2. Cardiovascular Drugs and Therapy 1990; 4: 767-776
3. Circulation 1995; 91: 1872-1885
4. International Journal of Cardiology 1997; 58: 95-117
5. Cardiovascular Drug Rev. 1989; 6: 292-312
6. Research & Clinical Forums 1995; 17(4): 21-26
7. Journal of Cardiovascular Surgery 1992; 33: 486-491